Editor's Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the July 23/30, 2014 issue
The PHOTON-1 investigators report that, after 12 or 24 weeks of treatment patients coinfected with HIV and hepatitis C virus who received an oral, interferon-free combination of sofosbuvir and ribavirin for 12 or 24 weeks had high rates of sustained virologic response.
This randomized trial assessed pregnancy incidence and birth outcomes among women using preexposure prophylaxis for HIV during the periconception period.
In a cluster randomized trial conducted in Blantyre, Malawi, MacPherson and coauthors investigated whether offering optional home initiation of HIV care after HIV self-testing might increase demand for antiretroviral therapy initiation, compared with HIV self-testing accompanied by facility-based services only.
Stanley and coauthors conducted a randomized clinical trial among 50 antiretroviral-treated men and women with human immunodefiency virus infection (HIV) and abdominal fat accumulation to investigate the effect of the growth hormone–releasing hormone analog tesamorelin on visceral adipose tissue and liver fat.
Günthard and coauthors report the 2014 recommendations of the International Antiviral Society–USA Panel on antiretroviral treatment of adult human immunodeficiency virus (HIV) infection.